<DOC>
	<DOCNO>NCT01702636</DOCNO>
	<brief_summary>The aim study test intracerebral haemorrhage ( ICH ) patient contrast extravasation compute tomography angiography , `` spot sign '' , low rate haematoma growth treat tranexamic acid within 4.5 hour stroke onset , compare placebo .</brief_summary>
	<brief_title>STOP-AUST : The Spot Sign Tranexamic Acid On Preventing ICH Growth - AUStralasia Trial</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Cerebral Hemorrhage</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>Patients present acute ICH Contrast extravasation within haemorrhage , `` spot sign '' , evaluate CTA accord three criterion , must present : 1 . Serpiginous spotlike appearance within margin parenchymal haematoma without connection outside vessel ; 2 . The density ( Hounsfield unit ) great background haematoma ( site investigator require document density ) ; 3 . No hyperdensity correspond location noncontrast CT. Age â‰¥18 year Treatment commence within 1 hour initial CT within 4.5 hour symptom onset ( patient unknown time symptom onset , time patient last know well ) Informed consent receive accordance local ethic committee requirement Glasgow coma scale ( GCS ) total score &lt; 8 Brainstem ICH ICH volume &gt; 70 ml measure ABC/2 method ICH know suspect study investigator secondary trauma , aneurysm , vascular malformation , haemorrhagic transformation ischaemic stroke , cerebral venous thrombosis , thrombolytic therapy , tumor , infection Contrast already administer within 24 hour prior initial CT contraindication image CT contrast agent ( e.g . know suspected iodine allergy significant renal failure ) Any history current evidence suggestive venous arterial thrombotic event within previous 12 month , include clinical , ECG , laboratory , image finding . Clinically silent chance finding old ischemia consider exclusion . Hereditary acquire haemorrhagic diathesis coagulation factor deficiency . Use heparin , lowmolecular weight heparin , GPIIb/IIIa antagonist , oral anticoagulation ( e.g . warfarin , factor Xa inhibitor , thrombin inhibitor ) within previous 14 day , irrespective laboratory value Pregnancy ( woman childbearing potential must test ) Planned surgery ICH within 24 hour Concurrent plan treatment haemostatic agent ( e.g . prothrombin complex concentrate , vitamin K , fresh frozen plasma , platelet transfusion ) Participation investigational study last 30 day Known terminal illness plan withdrawal care comfort care measure . Any condition , judgment investigator could impose hazard patient study therapy initiate affect participation patient study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Intracerebral Hemorrhage</keyword>
	<keyword>ICH</keyword>
	<keyword>Stroke</keyword>
	<keyword>Cerebrovascular Disorders</keyword>
	<keyword>Brain Diseases</keyword>
	<keyword>Central Nervous System Diseases</keyword>
	<keyword>Nervous System Diseases</keyword>
	<keyword>Vascular Diseases</keyword>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Tranexamic Acid</keyword>
	<keyword>Antifibrinolytic Agents</keyword>
	<keyword>Fibrin Modulating Agents</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Cardiovascular Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Hematologic Agents</keyword>
	<keyword>Hemostatics</keyword>
	<keyword>Contrast Media</keyword>
	<keyword>Angiography</keyword>
	<keyword>Cerebral Angiography</keyword>
	<keyword>Tomography , X-Ray Computed</keyword>
</DOC>